An Infectious Disease Update on Antibiotics: Emerging Resistance

Clinics in Podiatric Medicine and Surgery

Volumn 24, Issue 2, 2007, Pages 285-309

  Steinberg, John S ^a   Kim, Paul J ^b   Abbruzzese, Mark R ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOPENICILLANIC ACID; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; DICLOXACILLIN; ERYTHROMYCIN; MACROLIDE; NAFCILLIN; PENICILLIN G; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG;

BACTERIAL INFECTION; BITE WOUND; BONE INFECTION; BURN; DIABETIC FOOT; GAS GANGRENE; GONORRHEA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; NECROTIZING FASCIITIS; OSTEOMYELITIS; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FOOT DISEASES; HUMANS;

EID: 34147132177     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2007.01.002     Document Type: Review

References (57)

1. Barrett T.W., and Moran G.J. Update on emerging infections: news from the centers for disease control and prevention. [commentary]. Ann Emerg Med 43 (2004) 45-47
2. Chambers H.F. The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis 7 (2001) 178-182
3. Cohen P.R., and Kurzrock R. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 50 (2004) 277-280
4. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 7 (2006) 666-674
5. Grayson M.L., Gibbons G.W., Balogh K., et al. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. J Am Med Assoc 273 (1995) 721-723
6. Stevens D.L., Bisno A.L., Chambers H.F., et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
7. Ertugrul M.B., Baktiroglu S., Salman S., et al. The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labeled leukocyte scanning. Diabet Med 23 6 (2006) 649-653
8. Zeillemaker A.M., Veldkamp K.E., van Kraaij M.G., et al. Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int 19 (1998) 169-172
9. Lipsky B.A., Berendt A.R., Deery H.G., et al. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39 (2004) 885-910
10. Lipsky B.A., Armstrong D.G., Citron D.M., et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366 9498 (2005) 1695-1703
11. Denis O., Deplano A., Nonhoff C., et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 50 8 (2006) 2680-2685
12. Goldstein E.J.C., Citron D.M., Merriam C.V., et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 50 11 (2006) 3959-3962
13. Gesser R.M., McCarroll K.A., and Woods G.L. Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus pipercillin-tazobactam. Int J Antimicrob Agents 23 3 (2004) 235-239
14. Grayson M.L., Gibbons G.W., Habershaw G.M., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 18 (1994) 683-693
15. Tice A.D. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 53 Suppl 2 (2004) ii83-ii86
16. van der Linden P.D., van de Lei J., Nab H.W., et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 48 (1999) 433-437
17. van der Linden P.D., Sturkenboom M.C.J.M., Herings R.M.C., et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 324 (2002) 1306-1307
18. Roberge R.J., Kaplan R., Frank R., et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 36 2 (2000) 160-163
19. Kara M., Hasinoff B.B., McKay D.W., et al. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 31 3 (1991) 257-261
20. Frost R.W., Lasseter K.C., Noe A.J., et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. J Antimicrob Chemother 36 4 (1992) 830-832
21. Wang S., and Rizvi A.A. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci 331 6 (2006) 334-335
22. Giordano P., Song J., Pertel P., et al. Sequential intravenous/oral moxifloxacin versus intravenous pipercillin-tazobactam followed by oral amoxicillin-clavulanate for treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 26 5 (2005) 357-365
23. Conrad D.A., Williams R.R., Couchman T.L., et al. Efficacy of aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa. Rev Infect Dis S7 (1991) S634-S639
24. Scully B.E., and Neu H.C. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med 78 2 (1985) 251-261
25. Rodriguez C.N., Rodriguez-Morales A.J., Garcia A., et al. Antimicrobial resistance of Pseudomonas aeruginosa strains isolated from surgical infections in a 7-year period at a general hospital in Venezuela. Surg Infect 7 3 (2006) 269-273
26. Tomasoni D., Gattuso G., Chiarelli C., et al. Epidemiological surveillance of multi-drug resistant Pseudomonas aeruginosa in Montova hospital Italy. Infez Med 14 2 (2006) 85-91
27. Sarrubi F.A., and Hull J.W. Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med 85 (1976) 183-189
28. Verpooten G.A., Giuliano R.A., Verbist L., et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 45 (1989) 22-27
29. Preston S.L., and Briceland L.L. Single daily dosing of aminoglycosides. Pharmacotherapy 15 (1995) 297-316
30. Ferriols-Lisart R., and Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 53 10 (1996) 1141-1150
31. Baltch A.L., Bassey C., Hammer M.C., et al. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother 27 6 (1991) 801-808
32. Kaka A.S., Rueda A.M., Shelburne S.A., et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58 3 (2006) 680-683
33. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 24 Suppl 1 (1997) S63-S66
34. Capoor M.R., Nair D., Deb M., et al. Resistance to erythromycin and rising penicillin mic in Streptococcus pyogenes in India. Jpn J Infect Dis 50 5 (2006) 334-336
35. Ruhe J.J., Monson T., Bradsher R.W., et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 40 10 (2005) 1429-1434
36. Carter M.K., Ebers V.A., Younes B.K., et al. Doxycycline for community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. Ann Pharmacother 40 9 (2006) 1693-1695
37. Doan T.L., Fung H.B., Mehta D., et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 28 8 (2006) 1079-1106
38. Peterson L.R., Quick J.N., Jensen B., et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. Arch Intern Med 150 10 (1990) 2151-2155
39. Walsh T.J., Standiford H.C., Reboli A.C., et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 37 6 (1993) 1334-1342
40. Lipsky B.A., Itani K., and Norden C. Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multi-center, open-label trial of linezolid versus ampicillin-sublactam/amoxicillin-clavulanate. Clin Infect Dis 38 1 (2004) 17-24
41. Cepeda J.A., Whitehouse T., Cooper B., et al. Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53 (2004) 345-355
42. Lavery S., Ravi H., McDaniel W.W., et al. Linezolid and serotonin syndrome. Psychosomatics 42 (2001) 432-434
43. Wigen C.L., and Goetz M.B. Serotonin syndrome and linezolid. Clin Infect Dis 34 (2002) 1651-1652
44. Allington D.R., and Rivey M.P. Quinupristin/daltopristin: a therapeutic review. Clin Ther 23 1 (2001) 24-44
45. Nichols R.L., Graham D.R., Barriere S.L., et al. Syndercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, mutlicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 44 (1999) 263-273
46. Tally F.P., Zeckel M., Wasilewski M.M., et al. Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig Drugs 8 8 (1999) 1223-1238
47. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 (2004) 994-1000
48. Anastasiou D.M., Thorne G.M., Luperchio S.A., et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 28 5 (2006) 385-388
49. Freeman C.D., Quintiliani R., and Nightingale C.H. Vancomycin therapeutic drug monitoring: is it necessary?. Ann Pharmacother 27 (1993) 594-598
50. Cantu T.G., Yamanaka-Yuen N.A., and Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18 (1994) 533-543
51. Saunders N.J. Why monitoring peak vancomycin concentrations?. Lancet 344 (1994) 1748-1750
52. Shalansky S. Rationalization of vancomycin serum concentrations monitoring. Can J Hosp Pharm 48 (1995) 17-24
53. Creekmore F. Vancomycin levels: to draw or not to draw. S D J Med 51 (1998) 195-196
54. Stevens D.L. Teicoplanin for skin and soft tissue infections: an open study and a randomized, comparative trial versus cefazolin. J Infect Chemother 5 1 (1999) 40-45
55. Chirurgi V.A., Edelstein H., Oster S.E., et al. Randomized comparison trial of teicoplanin i.v., teicoplanin i.m., and cefazolin therapy for skin and soft tissue infections caused by gram-positive bacteria. South Med J 87 9 (1994) 875-880
56. Goldstein E.J.C., Citron D.M., Merriam C.V., et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47 6 (2003) 1968-1971
57. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415